VYTRUS BIOTECH

Trading sesion


13/02/2026 Close

11.8000

Last price


90.09 mill. €

Capitalisation

0.00

Dif.(%)


38.01

% Year 2026

Last Trade

Date

13/02/2026

Hour

Close

Last

11.8000

Ref.

11.8000

Dif.(%)

0.00

Volume (Shares)

7,530

Turnover (€x1000)

88.15

X
13/02/2026 17:41:39
BidAsk
OrdersVolumePricePriceVolumeOrders
1711.700011.90006324

Security

Security name

VYTRUS BIOTECH

Ticker

VYT

ISIN

ES0105618005

NIF

A-65118531

Shares Admitted

7.635.100

Nominal

0,01 Euros

Capital Admitted

76.351,00 Euros

Trading

Continuo

Liquidity Provider

GVC GAESCO VALORES, S.V., S.A.

Registered Advisor

GVC GAESCO VALORES, S.V., S.A.

Auditor

RSM SPAIN AUDITORES S.L.P.

Address

SANT GAIET 121, 08221 TERRASSA, BARCELONA

Contact

investors@vytrus.com

Historical Summary

 20222023202420252026 until 13/02

Capital Admitted (thousands of euros)

7171767676

Shares (x 1,000)

7,1157,1157,6357,6357,635

Period Close Price (euros)

3.40001.86002.16008.550011.8000

Period Last Price (euros)

3.40001.86002.16008.550011.8000

Period High Price (euros)

4.00003.50002.60009.800013.3000

Period Low Price (euros)

2.06001.78001.84002.12007.8500

Capitalisation (thousands of euros)

24,19113,23416,49265,28090,094

Volume (thousands of shares)

5413678331,884286

Turnover (thousands of euros)

1,7659571,89811,9402,917

"Our biotech platform of plant stem cell cultivations creates a new paradigm in dermo-cosmetics: beauty as a consequence of health and not the other way around."

Company Profile

Vytrus Biotech's goal is to be a benchmark in the dermo-cosmetic ingredients sector in innovation and sustainability through our biotechnological platforms of plant stem cell cultures. We promote skin health to improve people's appearance and well-being.

At Vytrus Biotech we develop, produce and market worldwide high value-added active ingredients in the dermo-cosmetic market. Plant stem cell technology has enormous potential not only in dermo-cosmetics but also in other sectors such as veterinary medicine, functional food and pharmaceuticals.

For the first time, technology and nature can be combined in a single product. Vytrus Biotech's biotechnology gives it a competitive advantage over traditional plant extracts. We obtain highly effective, sustainable and safe products, generating savings of more than 99% in natural resources and contributing to the preservation of the planet's biodiversity.

Inside Information

Other Relevant Information

Significant Shareholdings and Treasury Shares

Managers and related parties transactions

Financial Reports

Photo Gallery

To obtain detailed information or information in other formats, please contact BME Market Data at marketdata@grupobme.es or visit the website www.bmemarketdata.es.

The information provided by the different websites of Grupo BME is for internal use only. For any commercial use and/or other usage that involves the redistribution of the information to third parties for a fee, it is required a prior and express permission from BME Market Data. Please contact us at marketdata@grupobme.es.